Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioblastoma 9Neoplasms 3Medulloblastoma 2Brain Neoplasms 2Sarcoma 1Recurrence 1Pancreatic Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Gliosarcoma 1Glioma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Temozolomide 10Radiotherapy 5Radiation 4Magnetic Resonance Spectroscopy 4Ipilimumab 3pembrolizumab 2Specimen Handling 2Photons 2Nivolumab 2veliparib 1sargramostim 1peposertib 1montanide ISA 51 1liposomal doxorubicin 1cemiplimab 1balstilimab 1abexinostat 1X-Rays 1Vorinostat 1Utrogestan 1Surgical Procedures, Operative 1Sonication 1Progestins 1Progesterone 1Perfusion Magnetic Resonance Imaging 1Mycophenolic Acid 1Lomustine 1Irinotecan 1Drug Therapy 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gliosarcoma × Lomustine × 90 days × Clear all
NCT05095376 2026-05-19

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

NRG Oncology

Phase 3 Active not recruiting
265 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡